In 2002, the first III generation antipsychotic drug was registered—aripiprazole. Its partial
dopaminergic agonism underlies its unique mechanism of action and the potentially …

Abstract In 1979, the late Dr. Darrell R. Abernethy and colleagues began a series of clinical
studies aimed at understanding the pertinent determinants of drug distribution, elimination …

Background For psychotic disorders (ie schizophrenia), pharmacotherapy plays a key role in
controlling acute and long-term symptoms. To find the optimal individual dose and dosage …

Obesity is a serious condition with many known comorbid conditions and other health risks.
Despite the rising global rates of obesity, drug disposition in this population is typically …

Physiologically‐based pharmacokinetic (PBPK) modeling offers a viable approach to predict
induction drug–drug interactions (DDIs) with the potential to streamline or reduce clinical …

Brexpiprazole is an oral antipsychotic agent indicated for use in patients with schizophrenia
or as adjunctive treatment for major depressive disorder. As obesity (body mass index≥ 35 …

Crizotinib is used for the treatment of c‐ros oncogene 1–positive advanced non–small‐cell
lung cancer. Triazole antifungal agents are widely used for invasive fungal infections in …

We aimed to study the impact of personalized medication based on drug-related genes for
schizophrenia patients with resistance to traditional drugs. One hundred and ten …

Brexpiprazole is an antipsychotic drug often used to help treat schizophrenia and major
depressive disorder. This review paper breaks down the drugs history including what it is …